source
- Eli Lilly's Alzheimer's drug mevidalen fails Phase 2 trialEli Lilly conducted a Phase 2 trial of mevidalen, a dopamine-modulating compound, in patients with mild to moderate Alzheimer's disease. The study did not meet its primary efficacy endpoints, indi…
- Trump administration withdraws Heidi Overton’s FDA nomination amid Senate support concernsThe Trump administration has pulled the nomination of Heidi Overton to become the U.S. Food and Drug Administration commissioner, saying she lacked sufficient backing to win Senate confirmation. T…